Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taro gets bad news

This article was originally published in The Tan Sheet

Executive Summary

Two class action suits allege Securities Exchange Act violations by generics firm Taro Pharmaceutical Industries. Suits say the company failed to disclose "adverse factors that were having a negative impact on Taro's financial performance" such as the "increased competitive pressures" the firm was experiencing in the generic drugs business. Philadelphia-based law firm Berger & Montague and New York-based firm Abbey Gardy allege that Taro disregarded hefty costs to develop its branded Rx drug business. Both complaints are filed on behalf of all Taro securities purchasers from Feb. 20 2003 to July 29, 2004...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts